| |
 |
 |
| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CFEM345DTW02 |
| Title of Study |
An observational, multicenter study of Femara® in
ER+ and/ or PgR+ breast cancer patients under
conditions of general clinical practice
|
| Primary Objective |
The of objective of this study is to evaluate safety of Femara® after administration of Femara® for 48 weeks under the conditions of general clinical practice |
| Number of Sites |
18 |
| Period of Study |
from 2009-03-27 to 2011-12-31 |
| Number of Patients |
100 |
| IRB Approval Date |
22-Jan-2009 |
| Publication Plan / Date |
30-Jun-2012 |
|
|
|
|
